UPCC 24422: Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in Hi

Brief description of study

The purpose of this study is to compare the safety and efficacy of an investigational product, ALVR105 (also known as Viralym-M), with placebo to find out which is better at preventing viral infections and/or related diseases. This study will also check for development of virus-specific T cells in blood.

We would like to rely on WCG IRB as the IRB of record for this study.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 09 Mar 2024. Study ID: 851765

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).